Ref: JSTL/BOD/BSE/2026-27/NOV 26 **Date: November 11, 2026**

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Outcome of Board Meeting held on 11.11.2026

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Wednesday, 11.11.2026 at 12:00 Noon at the registered office of the Company, considered and approved the following:

1. Unaudited Financial Results (standalone and consolidated) for the quarter and half year ended 30.09.2026. (**Attached**).

2. Limited review Reports (standalone and consolidated) for the quarter and half year ended 30.09.2026. (**Attached**).

3. Resignation of Mr. Krishna Sainadh Kodati as the Company Secretary and Compliance Officer of the Company, pursuant to his resignation letter dated 11.11.2026, w.e.f. 16.11.2026. (Details attached as ***Annexure I*).**

4. Appointment of Mr. Ashok Babu Yaramaneni as the Company Secretary and Compliance Officer of the Company w.e.f. 16.11.2026. (Details attached as ***Annexure I***)

The meeting concluded at 02:00 P.M.

This is for the information and records of the Exchange, please.

Thanking You.

Yours faithfully,
For Jeevan Scientific Technology Limited
KODATI KRISHNA SAI NADH
Digitally signed by KODATI KRISHNA SAI NADH
Date: 2026.11.11 14:07:23 +05'30'
Krishna Sainadh Kodati
Company Secretary and Compliance Officer

Encl as above

Annexure I

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026]

Particulars	Mr. Krishna Sainadh Kodati	Mr. Ashok Babu Yaramaneni
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation of Mr. Krishna Sainadh Kodati as Company Secretary and Compliance officer of the Company.	Appointment of Mr. Ashok Babu Yaramaneni, as Company Secretary and Compliance officer of the Company.
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Date of resignation letter: 11.11.2026. Relieving w.e.f. 16.11.2026.	**Date of appointment**: 16.11.2026 **Terms of appointment:** Appointment of Mr. Ashok Babu Yaramaneni as Company Secretary and Compliance officer of the Company w.e.f. 16.11.2026.
Brief profile (in case of appointment);	Not Applicable	Mr. Ashok Babu Yaramaneni is a qualified Company Secretary with over 18 years of experience in corporate governance, secretarial functions and regulatory compliance, particularly in listed companies. He possesses extensive expertise in the Companies Act, SEBI Regulations, investor relations, corporate actions, mergers, takeovers and capital market transactions. He is a member of the Institute of Company Secretaries of India (ICSI) and holds additional certifications in Securities Laws and Financial Markets.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2026
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from operations						
	(a) Net sales/income from operations	2087.08	1693.47	1,043.17	3,780.55	1,864.74	5,393.13
I	**Total revenue from operation**	**2,087.08**	**1693.47**	**1,043.17**	**3,780.55**	**1,864.74**	**5,393.13**
II	Other Income	56.34	26.13	26.30	82.48	64.10	118.78
III	**Total income (I+II)**	**2,143.42**	**1719.61**	**1,069.47**	**3,863.03**	**1,928.84**	**5,511.91**
IV	**Expenses**						
	(a) Cost of materials consumed	147.78	157.96	93.77	305.74	156.04	443.27
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade		-	-	-	-	-
	(c) Employee benefits expense	588.66	494.67	425.73	1,083.33	847.21	1,799.40
	(d) Finance costs	34.83	29.53	38.12	64.36	74.20	137.77
	(e) Depreciation and Amortization expense	152.13	142.57	144.72	294.70	294.31	565.45
	(f) Other Expenses	843.17	676.85	376.55	1,520.02	825.64	2,302.09
	Total Expenses (IV)	**1,766.57**	**1,501.57**	**1,078.89**	**3,268.15**	**2,197.40**	**5,247.97**
V	**Profit/ (Loss) before Tax (III-IV)**	**376.85**	**218.04**	**(9.42)**	**594.88**	**(268.56)**	**263.94**
VI	**Tax Expenses**						
	(a) Current tax	58.79	34.01	-	92.80	-	44.56
	(b) MAT Credit / (Entitlement)	28.48	16.81	-	45.29	-	(33.91)
	(c) Deferred tax	14.31	(21.38)	(0.88)	(7.07)	(44.02)	88.28
	Total tax expense	**101.58**	**29.44**	**(0.88)**	**131.02**	**(44.02)**	**98.93**
VII	**Profit(Loss) for the period/year (V-VI)**	**275.27**	**188.60**	**(8.54)**	**463.86**	**(224.54)**	**165.01**
VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	(8.08)	4.46	11.78	(3.62)	11.78	17.82
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss				-	-	
	B (i) Items that will be reclassified subsequently to profit or loss				-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss				-	-	
	Total other comprehensive income/(loss) for the period	**(8.08)**	**4.46**	**11.78**	**(3.62)**	**11.78**	**17.82**
IX	**Total Comprehensive income for the period (VII+VIII)**	**267.19**	**193.06**	**3.24**	**460.24**	**(212.76)**	**182.83**
X	**Paid Up equity share capital (Face value of Rs.10/- each)**	**2,008.02**	**2,008.02**	**1,583.40**	**2,008.02**	**1,583.40**	**1,991.90**
XI	**Other equity**						**5,337.88**
XII	**Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)**						
	a) Basic	1.38	0.95	(0.05)	2.33	(1.42)	0.83
	b) Diluted	1.37	0.94	(0.05)	2.31	(1.42)	0.98

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R. Venkateswara Rao

Notes to the Unaudited financial results

1 The above Unaudited standalone financial results of Jeevan Scientific Technology Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 11, 2026. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results for the quarter and Half Year ended September 30, 2026.

2 These above Unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.

4 Employee benefit expenses for the Quarter ending 30th September 2026 includes Rs.59.43 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".

5 The results for the Quarter and Half Year ended 30th September 2026 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

R. Venkateswara Rao

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th November, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Standalone UnAudited Assets and Liabilities As at 30 September 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	2,762.63	2,092.93
b) Other intangible assets	751.41	705.94
c) Land	188.60	-
d) Capital Work in Progress	-	-
e) Right of use assets	537.19	292.79
f) Financial Assets		
i)Investments	500.00	500.00
ii)Other financial assets	92.61	68.94
g) Other non current assets	962.29	1,207.54
h) Deferred tax asset (net)	-	-
	5,794.72	**4,868.13**
(2)Current Assets		
a) Inventories	152.80	161.41
b) Financial Assets		
i) Trade receivables	1,918.76	1,853.38
ii) Cash and cash equivalents	1,368.94	946.79
iii)Other financial assets	1,245.78	860.05
c) Current tax assets (net)	478.66	609.95
d) Other current assets	446.95	625.56
	5,611.89	**5,057.13**
TOTAL ASSETS	**11,406.62**	**9,925.27**
Equity and Liabilities		
Equity		
a) Equity Share Capital	2,008.02	1,991.90
b) Other Equity	5,871.60	5,337.88
	7,879.62	**7,329.77**
Liabilities		
(1)Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	819.53	635.10
(ii) Lease liabilities	458.71	244.44
b) Provisions	91.44	73.88
c) Deferred tax Liability (net)	3.58	10.65
	1,373.26	**964.07**
(2)Current Liabilities		
a)Financial liabilities		
i) Borrowings	662.65	522.93
ii) Lease liabilities	131.64	91.32
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	191.30	193.30
(b) Total Outstanding dues of creditors other than micro, small and medium enterprises	406.36	330.82
iv) Other financial liabilities	142.09	126.27
b) Other current liabilities	479.25	319.78
c) Provisions	140.44	47.01
d) Current tax liabilities (net)		
	2,153.74	**1,631.43**
TOTAL EQUITY AND LIABILITIES	**11,406.62**	**9,925.27**

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

R.Venkateswara Rao

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

Venkateswara Rao ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th November, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Standalone UnAudited Cash Flows for the Half Year Ended 30th September, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	For the Half year ended 30th Sept. 2026	For the year ended 31 March 2026
A.	**Cash flow from operating activities**		
	Net Profit/(loss) before tax	**594.88**	**263.94**
	Adjustments for:		
	Depreciation and amortisation expenses	294.70	565.45
	Dividend received	(2.65)	(11.56)
	Interest received	(51.27)	(32.14)
	Fair value (gain)/loss on financial assets measured at amortized cost, net	(1.81)	(3.61)
	Share based payments to employees	73.48	71.14
	Net foreign exchange loss/(gain)	(20.01)	(45.38)
	Finance cost	61.13	128.09
	Operating profit before working capital changes	**948.46**	**935.92**
	Changes in Working Capital		
	Inventories	8.61	(68.07)
	Trade receivables	(45.37)	(368.90)
	Current and non current financial assets	(407.60)	(200.40)
	Other current and non current assets	506.28	(435.62)
	Trade payables	73.55	250.64
	Other financial liabilities	15.82	19.54
	Other liabilities	159.47	87.11
	Provisions	110.96	24.63
	Cash generated from operations before Tax	**1,370.19**	**244.85**
	Taxes Paid	92.80	10.65
	Net cash from operating activity	**1,277.39**	**255.50**
B.	**Cash flow from investing activities**		
	Purchase of property, plant and equipment including capital advances and capital creditors	(1,442.86)	(1,135.39)
	Investment in subsidaries	-	(300.00)
	Dividend Received	2.65	11.56
	Movement in other bank balances		
	Interest Received	51.27	32.14
	Net cash used in investing activity	**(1,388.95)**	**(1,391.68)**
C.	**Cash flow from financing activity**		
	Repayment of non current borrowings	184.43	74.84
	Repayment of current borrowings	139.72	258.51
	Interest paid	(61.13)	(128.09)
	Dividend paid		
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	16.12	1,984.00
	Repayment of principle portion of lease liability	254.59	(126.86)
	Net cash generated in financing activity	**533.73**	**2,062.40**
	Net increase in cash and cash equivalents (A+B+C)	**422.15**	**926.21**
	Cash and cash equivalents at the beginning of the year/period	946.79	20.59
	Cash and cash equivalents at the end of the year/period	**1,368.95**	**946.79**

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

R. Venkateswara Rao

Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th November, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th Sep 2026
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	2316.89	1827.75	1,237.95	4,144.64	2,117.86	6,153.71
I	**Total revenue from operation**	**2,316.89**	**1,827.75**	**1,237.95**	**4,144.64**	**2,117.86**	**6,153.71**
II	Other Income	44.43	17.44	20.37	61.87	53.80	97.27
III	**Total income (I+II)**	**2,361.32**	**1,845.19**	**1,258.32**	**4,206.51**	**2,171.66**	**6,250.98**
IV	**Expenses**						
	(a) Cost of materials consumed	154.70	171.27	99.53	325.97	176.87	487.70
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade						-
	(c) Employee benefits expense	668.16	574.12	510.36	1,242.28	1012.13	2,164.38
	(d) Finance costs	48.12	44.09	54.96	92.21	108.86	203.94
	(e) Depreciation and Amortization expense	180.24	170.27	169.39	350.51	343.41	664.24
	(f) Other Expenses	922.59	787.09	421.00	1,709.68	900.29	2,519.98
	Total Expenses (IV)	**1,973.81**	**1,746.84**	**1,255.24**	**3,720.66**	**2,541.56**	**6,040.25**
V	**Profit/ (Loss) before Share of Profit/(Loss) from Associate (III-IV)**	**387.51**	**98.35**	**3.08**	**485.85**	**(369.90)**	**210.73**
VI	Share of Profit/ (Loss) from Associate accounted using Equity Method	(0.65)	**(0.69)**	-	**(1.34)**	-	**(1.53)**
VII	**Profit/ (Loss) before Tax (V-VI)**	**386.86**	**97.66**	**3.08**	**484.52**	**(369.90)**	**209.20**
VIII	**Tax expenses**						
	(a) Current tax	58.79	34.01	-	92.80	-	44.56
	(b) MAT Credit / (Entitlement)	28.48	16.81	-	45.29	-	(33.91)
	(c) Deferred tax	9.83	(40.14)	2.11	(30.31)	(48.96)	95.22
IX	**Profit/(Loss) for the period/year**	**289.76**	**86.97**	**0.97**	**376.74**	**(320.94)**	**103.33**
X	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	(8.08)	4.46	11.78	(3.62)	11.78	17.82
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss			-	-	-	-
	B (i) Items that will be reclassified subsequently to profit or loss			-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss			-	-	-	-
	Comprehensive Income for the period /year	**(8.08)**	**4.46**	**11.78**	**(3.62)**	**11.78**	**17.82**
XI	**Total Comprehensive Income for the period /year**	**281.68**	**91.43**	**12.75**	**373.12**	**(309.16)**	**121.15**
XII	**Paid Up Equity Share Capital (Face Value of Rs.10/- each)**	**2,008.02**	**2,008.02**	**1,583.40**	**2,008.02**	**1,583.40**	**1,991.90**
XIII	**Other equity excluding revaluation reserve**					-	**5,202.34**
XIV	**Earnings per Equity share**						
	a) Basic (Amount in Rupees)	1.45	0.44	0.01	1.89	(2.03)	0.52
	b) Diluted (Amount in Rupees)	1.44	0.43	0.01	1.88	(2.03)	0.61

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

R. Venkateswara Rao

XV	**Net profit attributable to:**						
	Owners of the company	357.21	54.48	(8.75)	411.69	(318.90)	115.08
	Non-Controlling interest	(67.45)	32.49	9.72	(34.95)	(2.04)	(11.75)
XVI	**Other comprehensive income attributable to:**						
	Owners of the company	(8.08)	4.46	11.78	(3.62)	11.78	17.82
	Non-Controlling interest			-	-	-	-
XVII	**Total comprehensive income attributable to:**						
	Owners of the company	349.13	58.94	3.03	408.07	(307.12)	132.90
	Non-Controlling interest	(67.45)	32.49	9.72	(34.95)	(2.04)	(11.75)

Notes to the Unaudited financial results

1 The above Unaudited consolidated financial results of Jeevan Scientific Technology Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 11, 2026. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results for the Quarter and Half Year ended Sep 30, 2026.

2 These above Unaudited consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").

3 The consolidated financial results include the results of the following entities:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Nayas Laboratories Private Limited	India	Subsidiary	59.26%
Naya Pharma Private Limited	India	Associate	31.03%

4 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.

5 Employee benefit expenses for the Quarter ending 30th September 2026 includes Rs.59.43 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".

6 The results for the Quarter and Half Year ended 30th September 2026 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

R. Venkateswara Rao

Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad.
Date: 11th November, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Consolidated UnAudited Assets and Liabilities As at 30th September, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	As at 30 Sep 2026	As at 31 March 2026
	Unaudited	Audited
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	3,280.30	2,543.63
b) Other intangible assets	751.41	705.94
c) Land	188.60	
d) Capital work in progress	566.13	471.05
e) Right of use assets	587.61	358.82
f) Financial Assets		
i)Investments	297.14	298.47
ii)Other financial assets	111.77	86.26
g) Other non current assets	962.29	1,207.54
h) Deferred tax asset (net)	26.99	-
	6,772.23	**5,671.71**
(2)Current Assets		
a) Inventories	342.65	302.74
b) Financial Assets		
i) Trade receivables	2,080.87	2,069.31
ii) Cash and cash equivalents	1,372.74	950.55
iii)Other financial assets	424.88	213.64
c) Current tax assets (Net)	499.29	624.30
d) Other current assets	633.72	826.47
	5,354.14	**4,987.00**
TOTAL ASSETS	**12,126.37**	**10,658.72**
Equity and Liabilities		
Equity		
a) Equity share capital	2,008.02	1,991.80
b) Other equity	5,683.89	5,202.34
Total equity	**7,691.91**	**7,194.23**
Non controlling interest	65.79	100.75
	7,757.70	**7,294.98**
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	1,166.21	1,009.92
(ii) Lease liabilities	482.40	287.21
b) Provisions	91.44	73.88
c) Deferred tax Liability (net)	-	3.33
	1,740.05	**1,374.34**
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	858.87	705.98
ii) Lease liabilities	168.38	125.31
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	263.25	222.12
than micro,small and medium enterprises	482.23	390.64
iv) Other financial liabilities	195.49	133.02
v) Other Financial Creditors		
b) Other current liabilities	519.93	365.31
c) Provisions	140.44	47.01
	2,628.60	**1,989.39**
TOTAL EQUITY AND LIABILITIES	**12,126.37**	**10,658.72**

for Jeevan Scientific Technology Limited

R.Venkateswara Rao

	Krishna Kishore Kuchipudi	Venkateswara Rao Ravipati
Plase: Hyderabad	Managing Director	Chief Financial Officer
Date: 11th November 2026	(DIN:00876539)	

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Consolidated Un Audited Cash flow for the half year ended 30th Sept, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	As at 30 Sep 2026	As at 31 March 2026
A.	**Cash flow from operating activities**		
	Net Profit before tax and extraordinary items	**482.23**	**210.73**
	Adjustments for:		
	Depreciation	350.51	664.24
	Adjustments on account of fairvalue measurement of lease deposits	-	(0.91)
	Dividend Received	(2.65)	(11.56)
	Remeasurement Gain/Loss on Defined Benefit plans	-	17.82
	Interest Received	(20.48)	(3.86)
	Foreign exchange loss/(gain)		-
	Share based payments to employees	73.48	71.13
	Interest paid	92.21	203.94
	Operating profit before working capital changes	**975.32**	**1,151.53**
	Changes in Working Capital		
	Inventories	(39.91)	(140.92)
	Trade receivables	(11.56)	(475.08)
	Current and non current financial assets	(211.24)	(58.64)
	Other current and non current assets	517.73	(860.29)
	Trade payables	132.71	295.05
	Other financial liabilities	62.47	(12.48)
	Other liabilities	154.62	101.75
	Provisions	110.99	51.37
	Cash generated from operations before Tax	**1,691.12**	**52.29**
	Tax Paid	92.80	10.65
	Net cash from operating activity	**1,598.32**	**41.64**
B.	**Cash flow from investing activities**		
	Purchase of fixed assets	(1,645.11)	(818.06)
	investments in fixed deposits and margin money deposits with banks	(25.51)	(8.02)
	Change in Non controling interest	-	112.50
	Dividend Received	2.65	11.56
	Acquisition of a subsidiary, net of cash acquired	-	(300.00)
	Interest Received	20.48	3.86
	Net cash used in investing activity	**(1,647.50)**	**(998.16)**
C.	**Cash flow from financing activity**		
	Proceeds from non current borrowings	156.30	(163.11)
	Repayment of current borrowings	152.90	364.68
	Interest paid	(92.21)	(203.94)
	Dividend paid		
	Proceeds from issuance of Equity Shares	16.13	1,984.00
	Repayment of Lease Liability	238.26	(98.80)
	Proceeds from share based paymnets		
	Net cash generated in financing activity	**471.37**	**1,882.84**
	Net increase in cash and cash equivalents (A+B+C)	**422.19**	**926.32**
	Cash and cash equivalents at the beginning of the year/period	950.55	24.23
	Cash and cash equivalents at the end of the year/period	**1,372.74**	**950.55**

for Jeevan Scientific Technology Limited

R. Venkateswara Rao

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

Venkateswara Rao Ravipati
Chief Financial Officer

Plase: Hyderabad
Date: 11th November 2026

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company"), for the quarter ended September 30, 2026 and year to date results for the period from April 01, 2026 to September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement basedon our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity',issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not expressan audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in termsof Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pavuluri & Co
Chartered Accountants
FRN : 012194S

RAJESH NOOKAVA RAPU

Digitally signed by RAJESH NOOKAVARAPU
Date: 2026.11.11 13:22:39 +05'30'

PAVULURI & CO. Chartered Accountants Firm Reg. No. 012194S HYDERABAD

CA.N.Rajesh
Partner
M.No : 223169
UDIN: 26223169MTSHSF1849

Place : Hyderabad
Date :11/11/2026

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiary together referred to as "Group") and its share of the net loss after tax and total comprehensive loss of its associate, for the quarter ended September 30, 2026 and year to date results for the period from April 01, 2026 to September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement basedon our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not expressan audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the interim financial results of the following entities: (i) M/s Nayas Laboratories Private Limited (Subsidiary); and (ii) M/s Naya Pharma Private Limited (Associate). The unaudited financial results and other unaudited financial information of the subsidiary have been furnished to us by the management and have been reviewed by us. The unaudited interim financial information of the associate has not been reviewed by us and has been certified by the management.

5. Based on our review conducted as stated in paragraph 3 above and based on the consideration of the review by us referred in paragraph 6 below and the management certified interim financial information of the associate referred in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

6. We have reviewed the interim financial information of the subsidiary M/s Nayas Laboratories Private Limited included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs 1,751.09 lakhs as at September 30, 2026, total revenues of Rs 230.95 lakhs and Rs 368.15 lakhs, total net profit/(loss) after tax of Rs 15.15 lakhs and Rs (85.79) lakhs and total comprehensive income/(loss) of Rs 15.15 lakhs and Rs (85.79) lakhs, for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, and net cash inflows of Rs 0.04 lakhs for the period from April 01, 2026 to September 30, 2026, as considered in the statement. This interim financial information has been reviewed by us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the review done by us as stated in paragraph 3 above.

7. The consolidated unaudited financial results also include the Group's share of net loss after tax of Rs 0.65 lakhs and Rs 1.34 lakhs and total comprehensive loss of Rs 0.65 lakhs and Rs 1.34 lakhs for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, as considered in the Statement, in respect of the associate M/s Naya Pharma Private Limited, whose interim financial information has not been reviewed by us. This interim financial information has been certified by the management and furnished to us, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on such management certified interim financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of these matters, including our reliance on the interim financial information of the associate certified by the management.

For Pavuluri & Co
Chartered Accountants
FRN : 012194S

PAVULURI & CO * Firm Reg. No. 012194S * HYDERABAD * Chartered Accountants *

RAJESH NOOKAVARAPU

Digitally signed by RAJESH NOOKAVARAPU
Date: 2026.11.11 13:23:21 +05'30'

CA.N.Rajesh
Partner
M.No : 223169
UDIN :26223169YNCZGN9049

Place : Hyderabad
Date :11/11/2026

Date: 11th November, 2026

To
The Managing Director
and
The Board of Directors
Jeevan Scientific Technology Limited

Subject: Resignation from the Office of Company Secretary & Compliance Officer

Dear Sir(s)/Madam,

I hereby tender my resignation from the position of **Company Secretary & Compliance Officer** of **Jeevan Scientific Technology Limited** with **effect from 16th November 2026**, due to unavoidable personal reasons that require my complete attention.

It has been a privilege to serve the Company during my tenure. I sincerely thank the Managing Director, the Board of Directors, and all my colleagues for the trust, guidance, and support extended to me throughout my association with the Company.

I request the Board to kindly accept my resignation with immediate effect and take the necessary steps to file the requisite forms and intimations with the Registrar of Companies, BSE Limited, and other statutory and regulatory authorities, as applicable.

Thanking you.

Yours faithfully,



Krishna Sainadh Kodati
Company Secretary & Compliance Officer
Membership No.: A69904